Imricor Medical Systems Inc (imr) Logo

Imricor Medical Systems Inc (IMR)

___:___ · Healthcare

IMR Chart


IMR's Principal Activity is the design, manufacture and sell MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -77.31%
vs ASX 200 (1yr) -84.46%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,385 of 2,413
Sector Rank 114 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies THC / PAB / CTE
EPS -$0.15
DPS $0.00
Book Value Per Share $0.22

Broker Consensus

IMR is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Imricor Medical Systems Inc (IMR) is a US based medical device company that seeks to address the current issues with traditional x-ray-guided ablation procedures through the development of MRI-guided technology. The Company's primary product offering, the Vision-MR Ablation Catheter is specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Burnsville Minnesot USA 55337
Registry Computershare
Auditor Baker Tilly Virchow Krause, LLP
Date Listed 30 Aug 2019

Upcoming Calendar (Forecasted)

Date Event
25/08/2022 Report (Interim)
23/02/2023 Report (Prelim)
07/04/2023 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Anita Messal Non-Executive Director Mar 2021

Ms Anita Messal

Non-Executive Director

Ms. Messal currently serves as the Chief Integration Officer at AccentCare where she is responsible for the successful integration of merged and acquired entities across all areas of the business, while delivering upon expected synergy. Ms. Messal has over 35 years of experience in the health care and benefits industry. Prior to AccentCare, she most recently served as President & Chief Operating Officer of PlanSource.In this role she was responsible for company technology & operations including all aspects of Technology, Product, Service Delivery, Legal, and Human Resources. Anita has experience in health plan services, health care delivery, care management, and benefits administration. She has worked with self-funded, fully insured and CMS funded care. Her customers and partners include large and midsize employers, health plans, insurance carriers, brokers, resellers, enterprise software companies and consumers. Ms. Messal has participated in fund raising from start-up through IPO and sale to strategic buyers and private equity. Anita has worked in both F100 and start-up companies with experience in public, private and non-profit businesses. Her experience includes working in domestic and international markets, with time spent developing programs and partnerships in the United Kingdom and Europe.

Mr Peter McGregor Non-Executive Director May 2019

Mr Peter McGregor

Non-Executive Director

Mr McGregor has over 30 years' experience in senior finance and management roles, including having been a partner in the investment banking firm of Goldman Sachs JBWere and a managing director in the institutional banking & markets division of Commonwealth Bank of Australia. He is also a former Chief Financial Officer of the ASX50 transport company, Asciano Limited (ASX: AIO), and Chief Operating Officer of ASX listed Australian Infrastructure Fund Limited (ASX: AIX). Mr McGregor is an experienced company director, and currently serves as Chairman of Nutrano Produce Group Pty Ltd, and is a director of Pivotal Systems Corporation (ASX: PVS) and the Brisbane Lions Australian Football Club.

Mr Mark Tibbles Non-Executive Director Sep 2014

Mr Mark Tibbles

Non-Executive Director

Mr Tibbles is an entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies. Mr Tibbles is currently a Board member of THE NERDERY, LLC,, Inc., Poiesis Medical LLC's Chief Strategy Officer and Executive Committee Member, the Managing Director of Strategic Stage Ventures, LLC. Prior to his current roles, Mr Tibbles was an owner and member of Intuitive Technology Group until it was sold in 2017. Mr Tibbles was also President and founder of PRC Consulting, Inc., a company specialising in the management and implementation of IT projects for Fortune 1000 companies, from 1998 until 2013, when PRC was sold.

Mr Steve Wedan Chief Executive Officer,President,Executive Chairman,Executive Director May 2006

Mr Steve Wedan

Chief Executive Officer,President,Executive Chairman,Executive Director

Mr Wedan co-founded the Company in 2006 and has served as CEO since that time. Mr Wedan is responsible for the overall management and strategic direction of the Company. Mr Wedan has over 30 years of experience in the medical device industry including design engineering of MRI and ultrasound systems for GE Healthcare, as well as Vice President and Chief Technology Officer for Applied Biometrics Inc. Immediately prior to co-founding Imricor, Mr Wedan founded and operated a technical consulting company, Wedan Technologies Inc., from 2000-2006. Mr Wedan is a member of various international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI. Mr Wedan currently serves on the Board of Directors of Medical Device Research Forum, Inc. and Water Rescue Innovations, Inc., as well as the Advisory Board of Poiesis Medical, LLC.

Mr Kobe Li Company Secretary N/A
Lori Milbrandt Chief Financial Officer N/A
Gregg Stenzel Chief Operating Officer N/A

Director Transactions

IMR directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
24/03/22 Mark Tibbles Buy +175,000 $0.29 $50,750 Off-market trade
24/03/22 Steve Wedan Buy +175,000 $0.29 $50,750 Off-market trade
07/05/21 Steve Wedan Issued 304,254 $2.00 $608,508 Issue of options
07/05/21 Mark Tibbles Issued 40,896 $2.00 $81,792 Issue of options
07/05/21 Peter McGregor Issued 40,896 $2.00 $81,792 Issue of options
07/05/21 Anita Messal Issued 38,340 $2.00 $76,680 Issue of options
14/05/20 Steve Wedan Issued 579,187 $1.34 $776,110 Issue of options
14/05/20 Mark Tibbles Issued 71,010 $1.34 $95,153 Issue of options
14/05/20 Doris Engibous Issued 66,571 $1.34 $89,205 Issue of options
14/05/20 Peter McGregor Issued 71,010 $1.34 $95,153 Issue of options
31/12/19 Steve Wedan Transfer 2,518,219 $1.195 $3,009,272 Off-market transfer
31/12/19 Steve Wedan Transfer 2,518,219 $1.195 $3,009,272 Off-market transfer
31/12/19 Mark Tibbles Issued 2,897 $1.195 $3,462 Conversion of convertible notes
31/12/19 Steve Wedan Issued 501 $1.195 $599 Conversion of convertible notes
24/12/19 Mark Tibbles Buy +30,000 $0.341 $10,230 Exercise of options
24/12/19 Mark Tibbles Exercise 30,000 $0.341 $10,230 Exercise of options

Director Interests

The current holdings of IMR directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Mark Tibbles 24/03/2022 4,581,878 4,756,878 526,806 N/A
Steve Wedan 24/03/2022 0 4,599,733 2,144,241 N/A
Anita Messal 31/12/2021 N/A N/A 38,340 N/A
Peter McGregor 31/12/2021 N/A N/A 246,906 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Mar 23, 2022.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Citicorp Nominees Pty Limited <Domestic Hin A/C> 19,209,476 13.41%
J P Morgan Nominees Australia Pty Limited 12,269,784 8.56%
Hsbc Custody Nominees (Australia) Limited 12,023,548 8.39%
Siemens Medical Solutions Usa Inc 8,384,150 5.85%
National Nominees Limited 8,137,737 5.68%
Warren G Herreid Ii 7,819,431 5.46%
Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 5,799,757 4.05%
Cs Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C> 5,702,642 3.98%
Merrill Lynch (Australia) Nominees Pty Limited 3,260,798 2.28%
Kahr Foundation 2,950,988 2.06%
Steven R Wedan 2,518,720 1.76%
Bauer Private Equity Fund Vi Llc 1,696,555 1.18%
Steven R Wedan & 1,427,373 1.00%
Henry R Halperin 1,300,000 0.91%
Ronald D Berger 1,300,000 0.91%
Fleitman Koppa Investments Llc 901,530 0.63%
Albert C Lardo And Jennifer S Lardo 900,333 0.63%
Pensco Trust Company Llc <Davis Cartwright A/C> 867,896 0.61%
Bnp Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 836,581 0.58%
Johns Hopkins University 698,180 0.49%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 219 239 126 324 72 980

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Warren G Herreid II and KAHR Foundation 23/03/2022 10,771,092 7.52
BlackRock Group 23/03/2022 17,529,317 12.23
Regal Funds Management Pty Limited 23/03/2022 8,311,716 5.80
Siemens Medical Solutions USA Inc 23/03/2022 8,384,150 5.85
Saville Capital 23/03/2022 7,180,000 5.01

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
07-01-22 BlackRock Group 1,740,473 11.02 12.23
22-10-21 BlackRock Group 15,788,844 -- 11.02
20-09-21 BlackRock Investment Management Australia 7,596,885 6.98 10.86
14-09-21 Regal Funds Management Pty Limited 8,311,716 -- 5.84
10-09-21 One Funds Management Ltd 7,180,000 -- 5.05

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $1.95 30 June
2020 $1.49 30 June
IMR Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.